華邦健康(002004.SZ):子公司穎泰生物通過精選層掛牌輔導驗收
格隆匯3月16日丨華邦健康(002004.SZ)公佈,公司於2月18日披露了《關於控股子公司申報向不特定合格投資者公開發行股票並在精選層掛牌輔導備案的提示性公告》,公司控股子公司穎泰生物自2月18日起進入向不特定合格投資者公開發行股票並在精選層掛牌的輔導階段。
3月16日,穎泰生物收到北京證監局下發的《關於北京穎泰嘉和生物科技股份有限公司公開發行股票輔導工作的無異議函》(京證監發[2020]40號),穎泰生物在西南證券的輔導下已通過北京證監局的輔導驗收。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.